PHXM vs. COEP, ASLN, KTTA, IBIO, ATXI, PRTG, NEXI, VRPX, GNPX, and PALI
Should you be buying PHAXIAM Therapeutics stock or one of its competitors? The main competitors of PHAXIAM Therapeutics include Coeptis Therapeutics (COEP), ASLAN Pharmaceuticals (ASLN), Pasithea Therapeutics (KTTA), iBio (IBIO), Avenue Therapeutics (ATXI), Portage Biotech (PRTG), NexImmune (NEXI), Virpax Pharmaceuticals (VRPX), Genprex (GNPX), and Palisade Bio (PALI). These companies are all part of the "biotechnology" industry.
PHAXIAM Therapeutics (NASDAQ:PHXM) and Coeptis Therapeutics (NASDAQ:COEP) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, institutional ownership, earnings, profitability, analyst recommendations, dividends, valuation, risk and community ranking.
PHAXIAM Therapeutics has higher revenue and earnings than Coeptis Therapeutics.
Coeptis Therapeutics received 5 more outperform votes than PHAXIAM Therapeutics when rated by MarketBeat users.
PHAXIAM Therapeutics has a beta of 2.35, meaning that its share price is 135% more volatile than the S&P 500. Comparatively, Coeptis Therapeutics has a beta of -0.89, meaning that its share price is 189% less volatile than the S&P 500.
In the previous week, Coeptis Therapeutics had 4 more articles in the media than PHAXIAM Therapeutics. MarketBeat recorded 4 mentions for Coeptis Therapeutics and 0 mentions for PHAXIAM Therapeutics. Coeptis Therapeutics' average media sentiment score of 0.10 beat PHAXIAM Therapeutics' score of 0.00 indicating that Coeptis Therapeutics is being referred to more favorably in the news media.
Coeptis Therapeutics has a consensus price target of $3.00, suggesting a potential upside of 796.06%. Given Coeptis Therapeutics' higher possible upside, analysts plainly believe Coeptis Therapeutics is more favorable than PHAXIAM Therapeutics.
PHAXIAM Therapeutics' return on equity of 0.00% beat Coeptis Therapeutics' return on equity.
0.4% of PHAXIAM Therapeutics shares are held by institutional investors. Comparatively, 13.9% of Coeptis Therapeutics shares are held by institutional investors. 1.9% of PHAXIAM Therapeutics shares are held by insiders. Comparatively, 21.5% of Coeptis Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Summary
Coeptis Therapeutics beats PHAXIAM Therapeutics on 8 of the 13 factors compared between the two stocks.
Get PHAXIAM Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for PHXM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PHXM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
PHAXIAM Therapeutics Competitors List
Related Companies and Tools
